Drug Fails to Reduce Disability Risk in Primary-Progressive Multiple Sclerosis

December 1, 2014 3:56 PM

2 0

Novartis announced its analysis of fingolimod (Gilenya) in primary-progressive multiple sclerosis (PPMS) resulted in no significant difference from placebo, according to its phase 3 INFORMS study.

The study did not meet its primary endpoint of reducing the risk of 3-month sustained disability progression based on measures of the Expanded Disability Status Scale, upper limb function, and walking speed, according to Novartis.

Read more

To category page